AKI Therapeutics A/S: Financial statements 2018
CVR: 37509736
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -4,600 and a net result of DKK -4,608 compared with DKK -13,401 the year before. Equity in the 2018 report amounted to DKK 24,427. The solvency ratio was 16.9%.
- Gross Profit
- DKK -4,600
- Profit/Loss
- DKK -4,608
- Equity
- DKK 24,427
- Total Assets
- DKK 144,302
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -5K | -5K | 24K | - |
| 2017 | - | -4K | -13K | 29K | - |
| 2016 | - | -7K | -8K | 42K | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
AKI Therapeutics A/S has published its annual report for 2017. Gross profit came to DKK -4,000, and the net result was DKK -13,401.
As of February 5, 2018, Beier Holding ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 10%.
About AKI Therapeutics A/S
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.